---
title: "YCBD.US (YCBD.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/YCBD.US/news.md"
symbol: "YCBD.US"
name: "YCBD.US"
parent: "https://longbridge.com/en/quote/YCBD.US.md"
datetime: "2026-05-20T23:00:50.708Z"
locales:
  - [en](https://longbridge.com/en/quote/YCBD.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/YCBD.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/YCBD.US/news.md)
---

# YCBD.US (YCBD.US) — Related News

### [Analyst Reiterates Buy on cbdMD, Maintains $2 Price Target Amid Solid Revenue Momentum and Strategic Expansion](https://longbridge.com/en/news/286645337.md)
*2026-05-16T12:15:18.000Z*
> Analyst Anthony Vendetti from Maxim Group maintains a Buy rating on cbdMD with a $2 price target, citing strong revenue 

### [Cbdmd Inc Earnings Call: Growth Amid Margin Pressure](https://longbridge.com/en/news/286627322.md)
*2026-05-16T00:18:28.000Z*
> Cbdmd Inc reported Q2 earnings with net sales of $5.6 million, a 19% year-over-year increase. Despite revenue growth, th

### [cbdMD | 10-Q: FY2026 Q2 Revenue Beats Estimate at USD 5.64 M](https://longbridge.com/en/news/286461400.md)
*2026-05-14T20:16:22.000Z*
### [cbdMD Reports 19% Year-over-Year and 12% Sequential Revenue Growth; Bluebird Acquisition Integration and Medicare BEI Pathway Position Company for Continued Momentum | YCBD Stock News](https://longbridge.com/en/news/286460344.md)
*2026-05-14T12:10:26.000Z*
> cbdMD Reports 19% Year-over-Year and 12% Sequential Revenue Growth; Bluebird Acquisition Integration and Medicare BEI Pa

### [cbdMD, Inc. to Host Conference Call to Discuss March 31, 2026, Second Quarter Results | YCBD Stock News](https://longbridge.com/en/news/286144626.md)
*2026-05-12T11:05:32.000Z*
> cbdMD, Inc. to Host Conference Call to Discuss March 31, 2026, Second Quarter Results | YCBD Stock News

### [Candy-Coated Costs: How Unvalidated Hemp Gummies Found a Back Door Into Medicare](https://longbridge.com/en/news/285975421.md)
*2026-05-11T16:55:30.000Z*
> Taxpayers may face a potential $1.1 billion annual cost for unvalidated hemp-derived cannabinoid products under Medicare

### [12 Health Care Stocks Moving In Thursday's Pre-Market Session](https://longbridge.com/en/news/283830239.md)
*2026-04-23T12:07:49.000Z*
> In Thursday's pre-market session, Akanda (NASDAQ:AKAN) saw a significant gain of 49.9%, reaching $15.3, while West Pharm